IL-17A Binding Peptides for Blocking IL-17RA Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and inflammatory diseases driven by IL-17A signaling lack effective small molecule inhibitors due to the difficulty in targeting protein-protein interactions, necessitating the development of new molecules that can bind with high affinity to IL-17A and inhibit its interaction with IL-17RA.
Innovation Solution
Identification of peptides that specifically bind to the N-terminal portion of IL-17A, inhibiting its interaction with IL-17RA and the formation of the IL-17A/IL-17RA/IL17RC complex, thereby blocking the IL-17A signaling pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If small molecule inhibitors are used to target IL-17A, then the treatment can be administered orally with good patient compliance, but the inability to effectively bind to the protein-protein interaction interface results in insufficient inhibitory activity
Solution Approach 1:
The patent changes the molecular size parameter from small molecule to peptide scale, and modifies the chemical structure parameters by incorporating D-amino acids and N-terminal modifications. These parameter changes enable the inhibitor to achieve both high binding affinity (KD values in the nanomolar range) and oral bioavailability, resolving the contradiction between molecule size and functional effectiveness.
Solution Approach 2:
The patent creates composite peptide structures by combining D-amino acid residues with specific peptide sequences, and further composite structures by forming dimers linked via disulfide bonds or other linkers. This composite approach enhances binding affinity to the IL-17A interface while maintaining stability for oral administration.
2Reliability
If peptides are used to bind IL-17A with high affinity, then effective inhibition of the IL-17A/IL-17RA interaction is achieved, but the complexity of peptide synthesis and stabilization increases
Solution Approach 1:
The patent systematically changes the amino acid composition parameters by incorporating D-amino acids at specific positions and applying N-terminal modifications (acetylation, fatty acid attachment). These parameter changes stabilize the peptide structure against proteolytic degradation while maintaining or enhancing binding affinity to IL-17A, achieving high reliability without excessive complexity.
Solution Approach 2:
The patent segments the peptide into functional domains: N-terminal modification region for stability, core binding region for affinity, and C-terminal region for optional dimerization. This segmentation allows independent optimization of each region's function while simplifying the overall design and synthesis process.
3Reliability
If the peptide sequence is optimized for high binding affinity to IL-17A, then potent inhibition of inflammation is achieved, but the peptide becomes more susceptible to proteolytic degradation
Solution Approach 1:
The patent changes the chemical composition parameters by replacing L-amino acids with D-amino acids at strategically selected positions within the peptide sequence. This parameter change confers resistance to proteolytic enzymes while preserving the side chain interactions necessary for high-affinity binding to IL-17A, thereby maintaining inhibitory potency while enhancing stability.
Solution Approach 2:
The patent creates stable copies of the active peptide sequence by using D-amino acid analogs that mirror the binding interface requirements but resist degradation. The D-peptide copies maintain the three-dimensional structure and binding capability while being immunologically distinct and protease-resistant.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively reduce TH17-related inflammation and associated tissue damage in diseases where IL-17A plays a pivotal role, offering a novel therapeutic approach with improved tolerability and suitability for topical treatment.
Implementation Method 1
peptides that specifically bind to the N-terminal portion of IL-17A, inhibiting its interaction with IL-17RA and the formation of the IL-17A/IL-17RA/IL17RC complex
Data Source
AI summary
The invention relates to IL-17A binding peptides, inhibitors of the interaction of IL-17A with the receptor IL-17RA, and to bioconjugates, dimers, pharmaceutical compositions and medical use thereof.